BSE filing, NSE: WSFIN. Summary written from the filing by ALFA Finder's alert engine.
WSFx Global Pay Ltd: key numbers
- Share price
- ₹65.40
- Market cap
- ₹80.25 Cr
- Revenue (annual)
- ₹107.9 Cr
- Net profit (annual)
- ₹6.14 Cr
- P/E (TTM)
- 11.7×Sector 19.1×
- Promoter holding
- 56.94%-0.06% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from WSFx Global Pay Ltd
All →WSFx Global Pay Earnings Call Transcript: Key Takeaways
WSFx delivered record Q2 turnover growth led by student remittances, despite macro headwinds in the US market. The pivot toward high-volume B2B channels is driving scale but compressing margins due to higher commission payouts.
WSFx Global Pay Investor Presentation: Key Takeaways
Q2 FY27 revenue from operations ₹44.58 Cr (+30.0% YoY), PBT ₹5.33 Cr (+9.6%), gross turnover ₹2,914 Cr (+41.2%). Perpetual AD-II licence received 30 July 2026.
WSFx Global Pay Employee Stock Options
WSFx Global Pay allotted 1,62,500 ESOPs to eligible employees under its 2018 scheme, effective 27 October 2026. Options vest in tranches through October 2029.
WSFx Global Pay Capacity Expansion
WSFx Global Pay's board approved opening a new branch office in Kanpur, Uttar Pradesh, expected on or before December 15, 2026. The branch is part of the company's regional business expansion.
- new branches
- 1.0 branches
WSFx Global Pay Q2 FY27 Results: Net Profit ₹4.3 Cr, Up 16.2% YoY
WSFx Global Pay Ltd reported revenue from operations of ₹44.6 Cr (+30.0% YoY) and net profit of ₹4.3 Cr (+16.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹4.3 Cr · +16.2% YoY
WSFx Global Pay Board Meeting Date
WSFx Global Pay Limited scheduled a Board meeting for October 26, 2026, to consider and approve the unaudited financial results for the quarter ended September 30, 2026.
Other regulatory approval announcements
All →Gland Pharma Regulatory Approval
Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.
City Union Bank Regulatory Approval
City Union Bank disclosed RBI approval for appointing Shri Sankaran G as Executive Director (Whole-time Director) for three years. The board appointment and formal disclosures will follow later.
- Execution
- Three years from the date of taking charge
Lupin Regulatory Approval
Lupin received US FDA approval for its generic Amifampridine Tablets 10 mg ANDA. As a first-to-file applicant, it is eligible for 180-day shared generic exclusivity.
Som Distilleries & Breweries Regulatory Approval
Som Distilleries received manufacturing licences for its Bhopal plant from the Madhya Pradesh Excise Department, plus product label and rate approvals. Manufacturing and sales are expected to resume soon.
AGI Infra Regulatory Approval
Agi Infra received RERA registration PBRERA-SAS80-PR1452-102026 from Punjab RERA for its Utopia by AGI group housing project in New Chandigarh. The registration is valid until 30 March 2031.
- Execution
- Valid up to March 30, 2031
360 One Wam Regulatory Approval
360 ONE Distribution Services' IFSC branch, a subsidiary of 360 ONE WAM, received an IFSCA Certificate of Registration to act as broker dealer, clearing member, depository participant, research entity and distributor. This is a regulatory licence authorising new activities in the IFSC.